Latest Tax Incentives News

Page 2 of 64
RocketBoots has begun installing its global retail contract in US stores and received its first payment, but quarterly operating cash outflows of A$1.75 million left the company with an estimated 1.03 quarters of funding. Management is relying on incoming customer receipts, an R&D tax refund and a new A$5 million invoice financing facility to support the rollout.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.
Victor Sage
Victor Sage
30 Oct 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
PARKD has secured two early-stage contracts, added Symal as its exclusive partner in Victoria and South Australia, and lifted pro forma cash to about A$850,000 through a strategic placement. The progress comes against a sharp liquidity squeeze, with just A$53,000 in cash at 30 September and funding equivalent to 0.21 quarters before the raise.
Victor Sage
Victor Sage
30 Oct 2026
Eastern Gas has completed its Venus-2H horizontal appraisal well with 445 metres of interpreted coal contact, but the result now faces a more immediate test: whether the company can fund flow testing with only A$654,000 in cash. Gas deliverability remains unproven, while a proposed A$10 million R&D-backed facility is yet to be finalised.
Victor Sage
Victor Sage
30 Oct 2026
Australian Bond Exchange generated $1.68 million in positive operating cash flow in Q1 FY27, lifting cash to $1.49 million while repaying $436,000 of borrowings. The result strengthens its balance sheet, though the quarter’s cash inflows included $263,000 in government grants or tax incentives and $150,000 of interest received.
Victor Sage
Victor Sage
30 Oct 2026
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
Ada Torres
30 Oct 2026
Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.
Victor Sage
Victor Sage
30 Oct 2026
Red Metal is advancing a pre-feasibility study for a potential 20 Mtpa heap leach operation at Sybella, backed by encouraging Fresh Granite test work and a 5,000 metre drilling program. The company ended September with A$3.031 million in cash, equivalent to an estimated 1.9 quarters of funding at the current operating cash rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026

Browse the archive

Full archive